Investor Relations

AmpliPhi Biosciences Announces Appointment of Steve R. Martin as Chief Financial Officer

Tuesday, January 19, 2016 8:45 am EST

Dateline:

SAN DIEGO

Public Company Information:

NYSEMKT:
APHB
US03211P1030

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that Steve R. Martin has been appointed as its new Chief Financial Officer. He will be based in AmpliPhi’s San Diego office.

Mr. Martin brings over 30 years of progressive experience in senior financial roles including leadership positions in publicly-traded pharmaceutical companies. Mr. Martin served for three years as the CFO of Apricus Biosciences, a publicly-traded pharmaceuticals company. Prior to Apricus, he was CFO and interim CEO of BakBone Software, where he led the sale of the company to Quest Software. Previously, Mr. Martin was senior consultant to the CEO and Acting Chief Accounting Officer for Leap Communications, a $2 billion telecommunications company. Mr. Martin’s leadership experience includes serving as CFO of Stratagene Corporation, sold to Agilent Technologies in 2007 for $240 million and as Controller for Gen-Probe, acquired by Hologic. Mr. Martin began his career at Deloitte, where he spent 10 years in its San Diego office, rising to Senior Audit Manager. Mr. Martin has a B.S. in Accounting from San Diego State University and is the past President of the San Diego Chapter of Financial Executives International, a committee member of the Corporate Directors Forum and is a member of the San Diego Holiday Bowl Committee.

AmpliPhi’s interim CFO, David E. Bosher, remains with AmpliPhi as a consultant.

M. Scott Salka, CEO of AmpliPhi Biosciences, commented: “I would like to sincerely thank Dave for his tremendous and diligent contribution as our interim CFO, which helped our team accomplish several significant milestones in 2015. To capitalize on these successes, we must continue to attract and develop talented team members to help shepherd our first-in-class therapies to market. Steve brings to AmpliPhi a wealth of management experience and a proven ability to grow businesses, nurture talent and raise and manage capital. We are thrilled to welcome Steve to the team.”

About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation (NYSEMKT: APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi's product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (NYSE: XON), the U.S. Army, The Royal Brompton Hospital in London, UK and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies.

For more information, visit www.ampliphibio.com.

About Bacteriophage
Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defense for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.

Forward Looking Statements
Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about the potential use of bacteriophages to treat bacterial infections, including infections that do not respond to antibiotics, and AmpliPhi’s development of bacteriophage-based therapies. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon AmpliPhi’s current expectations and involve a number of risks and uncertainties, including the risks and uncertainties described in AmpliPhi’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and AmpliPhi undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Contact:

Company and Investor relations:
Matt Dansey
AmpliPhi Biosciences
+1 858-800-4869
md@ampliphibio.com
or
Media relations (USA)
Danielle Lewis/Glenn Silver
Lazar Partners
+1 212-867-1762
ampliphi@lazarpartners.com
or
Media Relations (Europe and ROW)
Gemma Howe/Sue Charles/Daniel Gooch
Instinctif Partners
+44 (0)20 7866 7905
ampliphi@instinctif.com

Business Wire InvestorHQsm